Abstract
Health administrations around the world are trying to decide whether they should add rotavirus vaccine to their countries' routine vaccination schedules. Two vaccines are available in the UK: Rotarix, from Glaxo SmithKline; and RotaTeq, from Sanofi Pasteur MSD. As with all decisions of this sort, the questions they need to answer will be: Can we afford it? Is the disease it could prevent serious? Does it work? How well does it work? Is it safe? Is it cost-effective (or, better still, cost-saving)?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
